Spots Global Cancer Trial Database for Prognostic Value of CTC in HNSCC Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Prognostic Value of CTC in HNSCC Patients

Official Title: Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer

Study ID: NCT01884129

Conditions

Recurrence

Metastasis

Death

Interventions

Study Description

Brief Summary: We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.

Detailed Description: 1. Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC) 2. Disease status: locally advanced or recurrent/metastasized at initial presentation 3. Age \>=20 years old 4. Could understand and signed the informed consents of this study 5. Enrolled patients were classified into three distinct subgroups: 1. Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT) because of some pathologic features such as positive margin, pathologic N2, and extracapsular spread (ECS) of involved lymph nodes indicating early relapse according to recommendation from National Comprehensive Cancer Network(NCCN) guidelines; 2. Patients with advanced disease directly underwent definitive concurrent chemoradiotherapy(CCRT); 3. Patients were to have palliative chemotherapy for existence of distant metastasis or poor general condition for definitive CCRT. 6. Blood samples were collected within 7 days before the first dose of chemotherapy.